Cargando…
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
Asthma is a widespread and heterogeneous inflammatory disease of the airways, which is characterized by several different phenotypes and endotypes. In particular, eosinophilic airway inflammation is a common pathologic trait of both allergic and nonallergic asthma. The key cytokine responsible for m...
Autores principales: | Pelaia, Corrado, Vatrella, Alessandro, Bruni, Andrea, Terracciano, Rosa, Pelaia, Girolamo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868576/ https://www.ncbi.nlm.nih.gov/pubmed/29606855 http://dx.doi.org/10.2147/DDDT.S155307 |
Ejemplares similares
-
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
por: Pelaia, Corrado, et al.
Publicado: (2018) -
Molecular Targets for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2020) -
Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma
por: Pelaia, Corrado, et al.
Publicado: (2020) -
Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021) -
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting
por: Vitale, Carolina, et al.
Publicado: (2023)